Navigation Links
Convergen LifeSciences Announces Patent Award
Date:7/14/2011

AUSTIN, Texas, July 14, 2011 /PRNewswire/ -- Convergen LifeSciences, Inc. announced today that another United States Patent 7,977,468 has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents and The Secretary, U.S. Department of Health and Human Services.  The patent is one of 23 patents, pending or issued worldwide, licensed exclusively to Convergen LifeSciences, Inc. The patent covers CNVN202, a targeted molecular cancer therapy undergoing clinical evaluation in lung cancer patients.

The '468 patent is based upon important discoveries made by a team of researchers from The University of Texas MD Anderson Cancer Center, The University of Texas Southwestern Medical Center and the National Cancer Institute. The discovery of the 3p21.3 family of tumor suppressor genes has been the subject of more than 20 peer-reviewed scientific publications demonstrating the genes' ability to control key anti-cancer mechanisms.  CNVN202 harnesses TUSC2 (FUS1), the most potent inducer of apoptosis among the family of 3p21.3 cancer suppressor genes.

"The patent further solidifies our growing IP portfolio," stated Greg Heinlein, Chief Operating and Financial Officer, Convergen LifeSciences. "Broadly speaking, this patent expands the application of CNVN202 to virtually all cancers and extends the use of our patented technologies to include cancer diagnostic and screening tools."

Data from a phase I clinical study presented at the 2011 annual meeting of the American Association for Cancer Research showed for the first time that a tumor suppressor gene can be delivered intravenously and selectively to human cancer cells using a nanoparticle vector, express high levels of mRNA and protein in cancer cells in the primary tumor and distant metastatic sites, alter relevant pathways in the cancer cell and mediate clinically beneficial anti-cancer activity.

A phase II clinical trial is planned to evaluate CNVN202 in combination with Tarceva® (erlotinib) in lung cancer patients who would not be expected to benefit from erlotinib alone.   CNVN202 has shown synergy when combined with erlotinib in both EGFR mutation positive and negative cancers.

Tarceva® is a registered trademark of the Roche Group including Genentech and Chugai and Astellas Pharma.  

Contact:
Greg Heinlein
Convergen LifeSciences, Inc.
(512) 372-4422
Email: gheinlein@convergenlifesciences.com
www.convergenlifesciences.com


'/>"/>
SOURCE Convergen LifeSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Drug Device Combination Market to 2016 - Technological Convergence to be the New Business Model for Growth and Profitability
2. Interdisciplinary Convergent Approach May Represent Future for Treatment of Atrial Fibrillation
3. Thought Leaders Shaping the Emerging Wireless Life Science Space to Share Vision and Insights at WLSA Convergence Summit
4. Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite
5. nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure
6. CPhI 2009: Madrid Launch for BioPh Marks Pharma and Biotech Convergence
7. TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS SciFinder®
8. Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan
9. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
10. Neuralstem Announces Notice of Allowance for Two Additional Neurogenic Compound Patents
11. Vapotherm Announces Approval in Canada for New High Flow Device Designed for Heliox
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2017)... -- Thornhill Research Inc. ( Toronto, Ontario, Canada ... five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by the U.S. Department ... ( Ottawa, Ontario, Canada ) to ... to patients requiring emergency medical procedures in a ... have been a longtime partner with Thornhill Research ...
(Date:5/10/2017)...  The Corporate Whistleblower Center says, "We are ... clinics to call us anytime at 866-714-6466 if they ... in a substantial scheme to overbill Medicare. We ... employee of a medical equipment company if their ... medical practice groups with extra generous incentives to use, ...
(Date:5/9/2017)... 9, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... today announced it has earned a spot on ... The Company was ranked among 500 U.S. employers as ... Healthcare Equipment and Services. The annual ... anonymous, independent survey of over 30,000 employees across 25 ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the flooring of ... District had left education officials with a number of critical issues to address before ... had to be accomplished with little or no disruption to class schedules. Second, the ...
(Date:5/24/2017)... ... , ... Altec Products, Inc., a leader in enterprise document management ... conference in San Diego, CA. , At nVerge 2017, Altec will be highlighting ... enhance their Sage ERP solutions by providing improved visibility and control to the entire ...
(Date:5/24/2017)... ... May 24, 2017 , ... Patients who want to receive cosmetic dentistry procedures ... Dr. Joseph Bedich for a consultation, with or without a referral. Dr. Bedich enjoys ... functionality. , Dr. Bedich offers a variety of cosmetic dentistry services at ...
(Date:5/24/2017)... Birmingham, Clarkston, Lake Orion, Michigan (PRWEB) , ... ... ... Endometriosis is a disease affecting the female reproductive tract in which ... itself on the pelvic structures causing inflammation and pain. Patients experiencing painful ...
(Date:5/24/2017)... ... May 24, 2017 , ... Adelberg-Montalvan ... dentistry options for its patients on Long Island, New York. , Holistic ... being, and is one of the biggest trends in dentistry today. , ...
Breaking Medicine News(10 mins):